Literature DB >> 28330421

The proteinopathy of D169G and K263E mutants at the RNA Recognition Motif (RRM) domain of tar DNA-binding protein (tdp43) causing neurological disorders: A computational study.

Vishwambhar Vishnu Bhandare1, Amutha Ramaswamy1.   

Abstract

One of the multitasking proteins, transactive response DNA-binding protein 43 (tdp43) plays a key role in RNA regulation and the two pathogenic mutations such as D169G and K263E, located at the RNA Recognition Motif (RRM) of tdp43, are reported to cause neurological disorders such as Amyotrophic Lateral Sclerosis and FrontoTemporal Lobar Degeneration. As the exploration of the proteinopathy demands both structural and functional characterizations of mutants, a comparative analysis on the wild type and mutant tdp43 (D169G and K263E) and their complexes with RNA has been performed using computational approaches. Molecular dynamics simulations revealed comparatively stable mutant structures compared to wild type tdp43. Both mutants show lesser binding affinity toward RNA molecule when compared to the wild type tdp43. Some of the observed features, including the increased solvent-accessible surface area, conformational flexibility as well as unfolding of tdp43, and the altered RNA conformation in tp43-RNA complex, reveal the susceptibility of these mutants to induce conformational changes in tdp43 for a possible aggregation in the cytoplasm. Particularly, the enhanced aggregation propensity of both mutants also evidences the higher probability of cytoplasmic aggregation of tdp43 mutants. Hence, the present analysis highlighting the structural and functional aspects of wild and mutant tdp43 will form the basis to gain insight into the proteinopathy of tdp43 and the related structure-based drug discovery. Thus, tdp43 can be used as target to develop novel therapeutic approaches or drug designing.

Entities:  

Keywords:  RRM domains; aggregation; molecular dynamics simulations; mutants; neurological disorders; tdp43

Mesh:

Substances:

Year:  2017        PMID: 28330421     DOI: 10.1080/07391102.2017.1310670

Source DB:  PubMed          Journal:  J Biomol Struct Dyn        ISSN: 0739-1102


  7 in total

1.  Aggregation of the nucleic acid-binding protein TDP-43 occurs via distinct routes that are coordinated with stress granule formation.

Authors:  Youjun Chen; Todd J Cohen
Journal:  J Biol Chem       Date:  2019-01-10       Impact factor: 5.157

2.  A3D 2.0 Update for the Prediction and Optimization of Protein Solubility.

Authors:  Jordi Pujols; Valentín Iglesias; Jaime Santos; Aleksander Kuriata; Sebastian Kmiecik; Salvador Ventura
Journal:  Methods Mol Biol       Date:  2022

3.  Protocols for Rational Design of Protein Solubility and Aggregation Properties Using Aggrescan3D Standalone.

Authors:  Aleksander Kuriata; Aleksandra E Badaczewska-Dawid; Jordi Pujols; Salvador Ventura; Sebastian Kmiecik
Journal:  Methods Mol Biol       Date:  2022

4.  Computational investigation of benzalacetophenone derivatives against SARS-CoV-2 as potential multi-target bioactive compounds.

Authors:  Pukar Khanal; Vishal S Patil; Vishwambhar V Bhandare; Prarambh S R Dwivedi; C S Shastry; B M Patil; Shailendra S Gurav; Darasaguppe R Harish; Subarna Roy
Journal:  Comput Biol Med       Date:  2022-05-27       Impact factor: 6.698

5.  Differential binding affinity of tau repeat region R2 with neuronal-specific β-tubulin isotypes.

Authors:  Vishwambhar Vishnu Bhandare; Bajarang Vasant Kumbhar; Ambarish Kunwar
Journal:  Sci Rep       Date:  2019-07-25       Impact factor: 4.379

6.  Aggrescan3D (A3D) 2.0: prediction and engineering of protein solubility.

Authors:  Aleksander Kuriata; Valentin Iglesias; Jordi Pujols; Mateusz Kurcinski; Sebastian Kmiecik; Salvador Ventura
Journal:  Nucleic Acids Res       Date:  2019-07-02       Impact factor: 16.971

Review 7.  Structural Insights Into TDP-43 and Effects of Post-translational Modifications.

Authors:  Liberty François-Moutal; Samantha Perez-Miller; David D Scott; Victor G Miranda; Niloufar Mollasalehi; May Khanna
Journal:  Front Mol Neurosci       Date:  2019-12-17       Impact factor: 5.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.